相似文献
1
COVID-19 Vaccines: Adenoviral Vectors.
Annu Rev Med. 2022 Jan 27;73:41-54. doi: 10.1146/annurev-med-012621-102252. Epub 2021 Oct 5.
2
Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines?
Virus Res. 2021 Sep;302:198466. doi: 10.1016/j.virusres.2021.198466. Epub 2021 Jun 1.
3
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.
4
Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
Rev Med Virol. 2021 May;31(3):e2183. doi: 10.1002/rmv.2183. Epub 2020 Oct 15.
5
The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine.
Viruses. 2023 Jan 11;15(1):204. doi: 10.3390/v15010204.
6
Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
J Virol. 2021 Nov 9;95(23):e0097421. doi: 10.1128/JVI.00974-21. Epub 2021 Sep 15.
7
Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
Antiviral Res. 2023 Aug;216:105656. doi: 10.1016/j.antiviral.2023.105656. Epub 2023 Jun 14.
8
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.
Mol Ther. 2021 Aug 4;29(8):2412-2423. doi: 10.1016/j.ymthe.2021.04.022. Epub 2021 Apr 23.
9
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
Immunol Rev. 2022 Sep;310(1):47-60. doi: 10.1111/imr.13088. Epub 2022 Jun 11.
10
Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims.
Inflamm Res. 2022 Jun;71(5-6):521-536. doi: 10.1007/s00011-022-01567-1. Epub 2022 Apr 10.
引用本文的文献
1
Global cis-regulatory landscape of double-stranded DNA viruses.
bioRxiv. 2025 Jul 20:2025.07.20.665756. doi: 10.1101/2025.07.20.665756.
2
Heterologous prime-boost immunization based on a human adenovirus 5 vectored containing Trichinella spiralis Cystatin-like protein elicits protective mucosal immunity in mice.
PLoS Negl Trop Dis. 2025 Jul 16;19(7):e0013323. doi: 10.1371/journal.pntd.0013323. eCollection 2025 Jul.
3
[Platform technologies in vaccine development].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Apr;68(4):368-377. doi: 10.1007/s00103-025-04024-6. Epub 2025 Mar 4.
4
Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8 T cell control of tumor challenge in mice.
J Immunother Cancer. 2024 Dec 18;12(12):e009644. doi: 10.1136/jitc-2024-009644.
5
Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation.
PeerJ. 2024 Dec 6;12:e18651. doi: 10.7717/peerj.18651. eCollection 2024.
6
Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.
Eng Microbiol. 2024 Feb 8;4(1):100140. doi: 10.1016/j.engmic.2024.100140. eCollection 2024 Mar.
7
FastAd: A versatile toolkit for rapid generation of single adenoviruses or diverse adenoviral vector libraries.
Mol Ther Methods Clin Dev. 2024 Oct 18;32(4):101356. doi: 10.1016/j.omtm.2024.101356. eCollection 2024 Dec 12.
8
Tolerability of a piezoelectric microneedle electroporator in human subjects.
Bioeng Transl Med. 2024 Mar 14;9(4):e10662. doi: 10.1002/btm2.10662. eCollection 2024 Jul.
9
Exploration of Gene Therapy for Alport Syndrome.
Biomedicines. 2024 May 23;12(6):1159. doi: 10.3390/biomedicines12061159.
10
Incidence and management of the main serious adverse events reported after COVID-19 vaccination.
Pharmacol Res Perspect. 2024 Jun;12(3):e1224. doi: 10.1002/prp2.1224.
本文引用的文献
1
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.
Nat Commun. 2021 Jul 26;12(1):4598. doi: 10.1038/s41467-021-24909-9.
2
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.
N Engl J Med. 2021 Sep 2;385(10):951-953. doi: 10.1056/NEJMc2108829. Epub 2021 Jul 14.
3
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8.
4
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
N Engl J Med. 2021 Sep 23;385(13):1172-1183. doi: 10.1056/NEJMoa2107659. Epub 2021 Jun 30.
5
Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine.
Ann Intern Med. 2021 Oct;174(10):1480-1482. doi: 10.7326/L21-0244. Epub 2021 Jun 29.
6
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.
Nature. 2021 Aug;596(7872):423-427. doi: 10.1038/s41586-021-03732-8. Epub 2021 Jun 23.
7
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Nature. 2021 Aug;596(7871):268-272. doi: 10.1038/s41586-021-03681-2. Epub 2021 Jun 9.
8
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565.
9
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity.
Lancet Infect Dis. 2021 Aug;21(8):1070. doi: 10.1016/S1473-3099(21)00262-0. Epub 2021 May 19.
10
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
Science. 2021 Aug 13;373(6556):818-823. doi: 10.1126/science.abh1139. Epub 2021 May 20.
Zotero 插件